Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.

Journal of the Formosan Medical Association = Taiwan yi zhi - 1 Feb 2021

Huang Cih-En, Wu Yu-Ying, Hsu Chia-Chen, Chen Ying-Ju, Tsou Hsing-Yi, Li Chian-Pei, Lai Yi-Hua, Lu Chang-Hsien, Chen Ping-Tsung, Chen Chih-Cheng

Abstract excerpt

BACKGROUND/PURPOSE: Ropeginterferon alpha-2b (Ropeg) is a novel pegylated interferon-alpha recently approved for the treatment of polycythemia vera (PV) in Europe. However, other than data from clinical trials, little is known about this agent in real world practice. METHODS: A compassionate use program employing Ropeg for treating patients with unmet medical need was initiated in Taiwan in 2017. Herein, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Europe

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polycythemia Vera

Share to Polyethylene Glycols

Share to Taiwan

Source

Identifiers

PMID: 32873465
DOI: 10.1016/j.jfma.2020.08.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.PMID 32873465Read ↗

Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.Semantic proximity Read ↗

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.Semantic proximity Read ↗

Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.Semantic proximity Read ↗

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

[Efficacy and safety of peginterferon-α2b for treatment of myeloproliterative neoplasms].Semantic proximity Read ↗

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?Semantic proximity Read ↗

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.Semantic proximity Read ↗

Real-life use of ropeg-interferon α2b in Polycythemia Vera: patient selection and clinical outcomesSemantic proximity Read ↗

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.Semantic proximity Read ↗

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivoSemantic proximity Read ↗

Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.